Results of research that identified new causes of Atherosclerotic Coronary Artery Disease, or ASCAD, have been reported by G3 Therapeutics (Global Genomics Group) and Aitia. The findings imply that LDL-TG could be a novel diagnostic marker for ASCAD and could also open up potential novel treatment targets for atherosclerosis, focusing on triglyceride-rich LDL particles.